Femasys is trading 13.7% up in pre-market at $1.99, compared with its October 12 close of $1.75; no clear company-specific overnight catalyst has surfaced. - Its latest identified announcement, on October 8, said it would exhibit fertility products at the ASRM congress later this month. - That announcement included no new clinical results, sales figures or commercial agreements. Available market context is mixed and does not clearly explain the sharp rise.